Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

G7048

Sigma-Aldrich

Proguanil hydrochloride

≥95% (HPLC)

Synonym(s):

Chlorguanide, N1-(4-Chlorophenyl)-N5-isopropylbiguanide

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
$83.25
50 MG
$315.90

$83.25

List price$92.50Save 10%
Web-Only Promotion

Available to ship onApril 08, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
10 MG
$83.25
50 MG
$315.90

About This Item

Empirical Formula (Hill Notation):
C11H16ClN5·HCl
CAS Number:
637-32-1
Molecular Weight:
290.19
EC Number:
211-283-7
MDL number:
MFCD01732193
UNSPSC Code:
51101906
PubChem Substance ID:
329799959
NACRES:
NA.77

$83.25

List price$92.50Save 10%
Web-Only Promotion

Available to ship onApril 08, 2025Details

Request a Bulk Order

Quality Level

100

assay

≥95% (HPLC)

form

solid

storage condition

desiccated

solubility

acetonitrile: water: ~1 mg/mL (60/40)

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1

InChI

1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H

InChI key

SARMGXPVOFNNNG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.

Biochem/physiol Actions

Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000053138
0000053137
0000186344
0000186343
050M4719V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Allan Pamba et al.
Blood, 120(20), 4123-4133 (2012-09-21)
Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous
Carine Van Malderen et al.
Malaria journal, 11, 139-139 (2012-05-02)
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy
Miriam K Laufer et al.
PloS one, 7(8), e42284-e42284 (2012-08-23)
The predominance of chloroquine-susceptible falciparum malaria in Malawi more than a decade after chloroquine's withdrawal permits contemplation of re-introducing chloroquine for targeted uses. We aimed to compare the ability of different partner drugs to preserve chloroquine efficacy and prevent the
Olivier Bouchaud et al.
Malaria journal, 11, 212-212 (2012-06-23)
Malaria continues to be amongst the most frequent infectious diseases imported to Europe. Whilst European treatment guidelines are based on data from studies carried out in endemic areas, there is a paucity of original prospective treatment data. The objective was
Patricia Schlagenhauf et al.
Expert review of anti-infective therapy, 10(5), 537-546 (2012-06-19)
The concept of 'standby emergency treatment' (SBET) describes the strategy where travelers carry an emergency malaria treatment for self-administration when no medical attention is available or for use under medical supervision after a confirmed malaria diagnosis, and raises many issues
View All Related Papers

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service